Akero: Positive End-of-Phase 2 FDA Meeting on NASH Therapy

 The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH

SYNCHRONY Histology and SYNCHRONY Real-World are expected to begin enrollment in the second half of this year

Consistent with the encouraging clinical profile to date reported for 28mg and 50mg EFX, Akero will continue to evaluate both doses in the Phase 3 SYNCHRONY program

https://finance.yahoo.com/news/akero-therapeutics-announces-positive-end-200100106.html